Anti-TNFRSF14/HVEM antibody [EPR28154-164],Abcam,AB314494

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

WB, IHC-P

Platform ID

BAB434924223

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-TNFRSF14/HVEM antibody [EPR28154-164]
Cat. No.AB314494
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationWB, IHC-P
ClonalityMonoclonal
Clone NumberEPR28154-164
Concentration0.513 - 0.525 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Receptor for four distinct ligands : The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signaling network (PubMed : 10754304, PubMed : 18193050, PubMed : 23761635, PubMed : 9462508). Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation (PubMed : 19915044, PubMed : 9153189, PubMed : 9162022). Participates in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions (PubMed : 10754304). Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumor immune response (PubMed : 23761635). In the context of bacterial infection, acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and pro-inflammatory cytokines (By similarity). Upon binding to CD160 on activated CD4+ T cells, down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (PubMed : 18193050). May interact in cis (on the same cell) or in trans (on other cells) with BTLA (By similarity) (PubMed : 19915044). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (By similarity) (PubMed : 19915044).. (Microbial infection) Acts as a receptor for Herpes simplex virus 1/HHV-1.. (Microbial infection) Acts as a receptor for Herpes simplex virus 2/HHV-2. See full target information TNFRSF14

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.